HealthcareNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 856982MMSI stock profile & AI dashboard →

13F Pro Quality Score

60.1/100

Rank #876 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

63.9/100

Profitability

63.9/100

Balance Sheet

69.7/100

Earnings Quality

65.6/100

Free Cash Flow

65.8/100

Institutional Flow

10.8/100

Revenue Scale

57.5/100

Dilution Risk

34.7/100

MMSI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MERIT MEDICAL SYSTEMS INC (MMSI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MMSI at 60.1/100 on a 32-signal composite quality model, placing it at rank #876 of 2,879 stocks — the top half of the AI-ranked universe. Areas of concern include institutional flow (10.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 34.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MERIT MEDICAL SYSTEMS INC reports quarterly revenue of $381.9M, net income of $41.0M, an operating margin of 11.6%. Top institutional holders of MMSI by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MMSI trades on the Nasdaq exchange and files with the SEC under CIK 856982. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MMSI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MERIT MEDICAL SYSTEMS INC directly from SEC EDGAR. MERIT MEDICAL SYSTEMS INC's 13F Pro composite quality score has ranged between 43 and 68 since 2021, currently 60.1 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

Revenue

Q1 2026

$381.9M

Net Income

Q1 2026

$41.0M

Free Cash Flow

Q1 2026

$24.7M

Operating Margin

Q1 2026

11.6%

ROIC

Q1 2026

1.9%

D/E Ratio

Q1 2026

0.45

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+11.8% YoY
$1.52BFY 2025
FY21 $1.07BFY23 $1.26BFY24 $1.36BFY25 $1.52B

Net Income

+6.8% YoY
$128.5MFY 2025
FY21 $48.5MFY23 $94.4MFY24 $120.4MFY25 $128.5M

Operating Income

+18.6% YoY
$184.7MFY 2025
FY21 $60.9MFY23 $123.9MFY24 $155.7MFY25 $184.7M

EPS (Diluted)

+4.9% YoY
$2.13FY 2025
FY21 $0.84FY23 $1.62FY24 $2.03FY25 $2.13

Total Assets

+11.1% YoY
$2.69BFY 2025
FY21 $1.65BFY23 $2.33BFY24 $2.42BFY25 $2.69B

Total Debt

+0.6% YoY
$734.0MFY 2025
FY21 $251.3MFY23 $823.0MFY24 $729.6MFY25 $734.0M

Op. Cash Flow

+34.7% YoY
$297.4MFY 2025
FY21 $147.2MFY23 $145.2MFY24 $220.8MFY25 $297.4M

AI Insight: MMSI Financial Trends

Revenue growth accelerated to 16.5% year-over-year in Q4 2025 while operating cash flow remained volatile, swinging from $99M to $41M quarter-over-quarter.

Revenue expanded from $338M in Q2 2024 to $382M in Q1 2026, with particularly strong growth in Q2 2025.

Total debt declined from $801M in Q2 2024 to $735M in Q1 2026, improving leverage profile.

Equity increased steadily from $1,282M in Q2 2024 to $1,627M in Q1 2026, strengthening balance sheet.

Net income volatility persisted, ranging from $28M to $41M across recent quarters with no clear trend.

Operating cash flow dropped sharply from $99M in Q4 2025 to $41M in Q1 2026, continuing erratic pattern.

Revenue declined 3% sequentially in Q1 2026 after strong Q4 2025 performance, raising sustainability questions.

AI Insight: MMSI Ratio Trends

Merit Medical shows volatile profitability with operating margins swinging from 10.3% to 13.8% over six quarters, while leverage steadily declined from 0.62 to 0.45 debt-to-equity.

Operating margin fluctuated significantly, ranging from 10.3% in Q4 2024 to 13.8% in Q4 2025.

Debt-to-equity ratio improved consistently from 0.62 in Q2 2024 to 0.45 in Q1 2026.

ROE recovered from 7.3% in Q3 2025 to 10.1% in Q1 2026.

ROIC declined from 9.3% in Q4 2025 to 7.5% in Q1 2026 despite strong ROE performance.

Operating margin volatility suggests inconsistent operational execution across quarters.

Get alerted when MMSI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MERIT MEDICAL SYSTEMS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of MMSI

Put MMSI on your watchlist

Track score changes the day MERIT MEDICAL SYSTEMS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is MMSI a good stock to buy?

13F Pro's AI-powered analysis of MERIT MEDICAL SYSTEMS INC (MMSI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MMSI are available on the MMSI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MMSI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MMSI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MERIT MEDICAL SYSTEMS INC's investment landscape.